Atypical antipsychotics, also known as second-generation antipsychotics, are commonly used to treat conditions such as schizophrenia, bipolar disorder, severe cases of dementia, anxiety disorder and autism.
Clinicians today tend to prescribe atypical antipsychotics instead of typical antipsychotics, which are first-generation treatment options. Industry trends also reveal an increasing range of on-label and off-label uses, according to a report published by the National Center for Biotechnology Information.
The American Diabetes Association and American Psychiatric Association have recommended that patients who will be prescribed antipsychotics receive more intensive screening for diabetes and abnormalities in lipids to combat health risks.
According to a report completed by the University of Colorado Anschutz Medical Campus:
"The biggest gap in screening is among adults age 40 and younger, the group for whom early detection and intervention has been shown to be effective when additional cardiovascular risk is present."